Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Abstract 1611: 4-protein signature predicts outcome to tamoxifen treatment in estrogen receptor positive recurrent breast cancer

Tommaso De Marchi, NingQing Liu, Mila Tjoa, Christoph Stingl, Marcel Smid, Maxime P. Look, Mieke A. Timmermans, Rene BH Braakman, Mark Opdam, Sabine Linn, Paul Span, Fred CGJ Sweep, John WM Martens, Theo M. Luider, John A. Foekens, Arzu Umar

Cancer Res (2014) 74 (19_Supplement): 1611.

https://doi.org/10.1158/1538-7445.AM2014-1611

Published: 01 October 2014

View articletitled, Abstract 1611: 4-protein signature predicts outcome to tamoxifen treatment in estrogen receptor positive recurrent breast cancer

Journal Articles

Abstract P4-09-03: Comparative proteomic analysis identifies a 15-protein signature related to clinical outcome of triple negative breast cancer

Ning Qing Liu, Tommaso De Marchi, Christoph Stingl, Annemieke M Timmermans, Maxime P Look, René BH Braakman, Marcel Smid, Renée Foekens, Anita MAC Trapman, Theo M Luider, John WM Martens, John A Foekens, Arzu Umar

Cancer Res (2012) 72 (24_Supplement): P4-09-03.

https://doi.org/10.1158/0008-5472.SABCS12-P4-09-03

Published: 15 December 2012

View articletitled, Abstract P4-09-03: Comparative proteomic analysis identifies a 15-protein signature related to clinical outcome of triple negative breast cancer

Journal Articles

Abstract 3668: Relevance of BCAR4 in tamoxifen resistance and tumor aggressiveness of breast cancer

Marcia F. E. Godinho, Anieta M. Sieuwerts, Maxime P. Look, Danielle Meijer, Stefan Sleijfer, John A. Foekens, Lambert C. J. Dorssers, Ton van Agthoven

Cancer Res (2010) 70 (8_Supplement): 3668.

https://doi.org/10.1158/1538-7445.AM10-3668

Published: 15 April 2010

View articletitled, Abstract 3668: Relevance of BCAR4 in tamoxifen resistance and tumor aggressiveness of breast cancer

Journal Articles

Abstract 1582: Identification of BCAR genes relevant for breast cancer progression and endocrine therapy resistance

Ton Van Agthoven, Jos Veldscholte, Anieta Sieuwerts, Marcel Smid, Marion E Meijer-Van Gelder, Maxime P Look, John A Foekens, Lambert C. J. Dorssers

Cancer Res (2008) 68 (9_Supplement): 1582.

https://doi.org/10.1158/1538-7445.AM2008-1582

Published: 15 May 2008

View articletitled, Abstract 1582: Identification of BCAR genes relevant for breast cancer progression and endocrine therapy resistance

Journal Articles

PITX2B mRNA expression is associated with poor prognosis in lymph node-negative steroid hormone receptor-positive breast cancer

John W. Martens, Anieta M. Sieuwerts, Marion E. Meijer-Van Gelder, Maxime P. Look, Joan Bolt-De Vries, Inko Nimmrich, Nadia Harbeck, Ralf Lesche, Oliver Hartmann, Henk Portengen, Manfred Schmitt, Sabine Maier, Jan Gm Klijn, John A. Foekens

Cancer Res (2006) 66 (8_Supplement): 847–848.

Published: 15 April 2006

View articletitled, PITX2B mRNA expression is associated with poor prognosis in lymph node-negative steroid hormone receptor-positive breast cancer

Journal Articles

FGFR 4 predicts failure on tamoxifen therapy in women with recurrent breast cancer.

Daniëlle Meijer, Anieta M. Sieuwerts, Maxime P. Look, Ton Van Agthoven, Mieke Timmermans, John A. Foekens, Lambert C J Dorssers

Cancer Res (2006) 66 (8_Supplement): 1346.

Published: 15 April 2006

View articletitled, FGFR 4 predicts failure on tamoxifen therapy in women with recurrent breast cancer.

Journal Articles

Association of DNA Methylation of Phosphoserine Aminotransferase with Response to Endocrine Therapy in Patients with Recurrent Breast Cancer

John W.M. Martens, Inko Nimmrich, Thomas Koenig, Maxime P. Look, Nadia Harbeck, Fabian Model, Antje Kluth, Joan Bolt-de Vries, Anieta M. Sieuwerts, Henk Portengen, Marion E. Meijer-Van Gelder, Christian Piepenbrock, Alexander Olek, Heinz Höfler, Marion Kiechle, Jan G.M. Klijn, Manfred Schmitt, Sabine Maier, John A. Foekens

Cancer Res (2005) 65 (10): 4101–4117.

https://doi.org/10.1158/0008-5472.CAN-05-0064

Published: 15 May 2005

View articletitled, Association of DNA Methylation of Phosphoserine Aminotransferase with Response to Endocrine Therapy in Patients with Recurrent Breast Cancer

Includes: Supplementary data

Journal Articles

DNA-hypermethylation of PITX2 and risk of breast cancer recurrence in lymph node-negative hormone receptor-positive breast cancer patients

John W. M. Martens, Sabine Maier, Ina Schwope, Thomas Koenig, Oliver Hartmann, Antje Kluth, Maxime P. Look, Nadia Harbeck, Joan Bolt-De Vries, Anieta M. Sieuwerts, Henk Portengen, Marion E. Meijer-Van Gelder, Manfred Schmitt, Jan G. M. Klijn, John A. Foekens, Inko Nimmrich

Cancer Res (2005) 65 (9_Supplement): 650.

Published: 01 May 2005

View articletitled, DNA-hypermethylation of PITX2 and risk of breast cancer recurrence in lymph node-negative hormone receptor-positive breast cancer patients

Journal Articles

VAV3 and its binding proteins SIAH2 and EZH2 predict tamoxifen resistance in metastatic breast carcinomas

Maurice P. Jansen, John A. Foekens, Iris L. Van Staveren, Kirsten Ritstier, Anieta M. Sieuwerts, Marion E. Meijer-Van Gelder, Maxime P. Look, Henk Portengen, Lambert C. Dorssers, Jan G. Klijn, Els M. Berns

Cancer Res (2005) 65 (9_Supplement): 511–512.

Published: 01 May 2005

View articletitled, VAV3 and its binding proteins SIAH2 and EZH2 predict tamoxifen resistance in metastatic breast carcinomas

Journal Articles

A functional Luteinizing Hormone Receptor variant predicts poor disease free survival of breast cancer patients.

Djura Piersma, Miriam Verhoef-Post, Maxime P. Look, Huibert A. Pols, Jan G. Klijn, Axel P. Themmen, Els M. Berns

Cancer Res (2005) 65 (9_Supplement): 114.

Published: 01 May 2005

View articletitled, A functional Luteinizing Hormone Receptor variant predicts poor disease free survival of breast cancer patients.

Journal Articles

Urokinase-Type Plasminogen Activator System in Breast Cancer: Association with Tamoxifen Therapy in Recurrent Disease

Marion E. Meijer-van Gelder, Maxime P. Look, Harry A. Peters, Manfred Schmitt, Nils Brünner, Nadia Harbeck, Jan G. M. Klijn, John A. Foekens

Cancer Res (2004) 64 (13): 4563–4568.

https://doi.org/10.1158/0008-5472.CAN-03-3848

Published: 01 July 2004

View articletitled, Urokinase-Type Plasminogen Activator System in Breast Cancer: Association with Tamoxifen Therapy in Recurrent Disease

Journal Articles

Stereo selective anti-tumor and anti-metastatic effects of the serine protease inhibitors: WX-UK1 and D-WX-UK1 administered to brown Norwegian rats bearing syngeneic BN-472 mammary tumor.

Buddy Setyono-Han, Wolfgang A. Schmalix, Anieta M. Sieuwerts, Bernd Muehlenweg, Mieke Timmermans, Viktor Magdolen, Maxime P. Look, Manfred Schmitt, Jan G. Klijn, John A. Foekens

Cancer Res (2004) 64 (7_Supplement): 472.

Published: 01 April 2004

View articletitled, Stereo selective anti-tumor and anti-metastatic effects of the serine protease inhibitors: WX-UK1 and D-WX-UK1 administered to brown Norwegian rats bearing syngeneic BN-472 mammary tumor.

Journal Articles

Quantitative BCAR1 protein levels in primary breast tumors are associated with early recurrence and failure of tamoxifen therapy

Lambert C. Dorssers, Nicolai Grebenchtchikov, Arend Brinkman, Maxime P. Look, Simone P. Van Broekhoven, Danielle De Jong, Harry A. Peters, Anneke Geurts-Moespot, Paul N. Span, Jan G. Klijn, John A. Foekens, Fred Sweep

Cancer Res (2004) 64 (7_Supplement): 240.

Published: 01 April 2004

View articletitled, Quantitative BCAR1 protein levels in primary breast tumors are associated with early recurrence and failure of tamoxifen therapy

Journal Articles

The Prognostic Value of Polymorphonuclear Leukocyte Elastase in Patients with Primary Breast Cancer

John A. Foekens, Christian Ries, Maxime P. Look, Cornelia Gippner-Steppert, Jan G. M. Klijn, Marianne Jochum

Cancer Res (2003) 63 (2): 337–341.

Published: 15 January 2003

View articletitled, The Prognostic Value of Polymorphonuclear Leukocyte Elastase in Patients with Primary Breast Cancer

Journal Articles

Enhanced Benefit from Adjuvant Chemotherapy in Breast Cancer Patients Classified High-Risk according to Urokinase-type Plasminogen Activator (uPA) and Plasminogen Activator Inhibitor Type 1 ( n = 3424)

Nadia Harbeck, Ronald E. Kates, Maxime P. Look, Marion E. Meijer-van Gelder, Jan G. M. Klijn, Achim Krüger, Marion Kiechle, Fritz Jänicke, Manfred Schmitt, John A. Foekens

Cancer Res (2002) 62 (16): 4617–4622.

Published: 15 August 2002

View articletitled, Enhanced Benefit from Adjuvant Chemotherapy in Breast Cancer Patients Classified High-Risk according to Urokinase-type Plasminogen Activator (uPA) and Plasminogen Activator Inhibitor Type 1 ( n = 3424)

Journal Articles

High Tumor Levels of Vascular Endothelial Growth Factor Predict Poor Response to Systemic Therapy in Advanced Breast Cancer

John A. Foekens, Harry A. Peters, Nicolai Grebenchtchikov, Maxime P. Look, Marion E. Meijer-van Gelder, Anneke Geurts-Moespot, Theo H. van der Kwast, C. G. J. (Fred) Sweep, Jan G. M. Klijn

Cancer Res (2001) 61 (14): 5407–5414.

Published: 01 July 2001

View articletitled, High Tumor Levels of Vascular Endothelial Growth Factor Predict Poor Response to Systemic Therapy in Advanced Breast Cancer

Journal Articles

Thymidine Kinase and Thymidylate Synthase in Advanced Breast Cancer: Response to Tamoxifen and Chemotherapy

John A. Foekens, Sylvie Romain, Maxime P. Look, Pierre-Marie Martin, Jan G. M. Klijn

Cancer Res (2001) 61 (4): 1421–1425.

Published: 02 February 2001

View articletitled, Thymidine Kinase and Thymidylate Synthase in Advanced Breast Cancer: Response to Tamoxifen and Chemotherapy

Journal Articles

Complete Sequencing of TP53 Predicts Poor Response to Systemic Therapy of Advanced Breast Cancer

Els M. J. J. Berns, John A. Foekens, Rolf Vossen, Maxime P. Look, Peter Devilee, Sonja C. Henzen-Logmans, Iris L. van Staveren, Wim L. J. van Putten, Mats Inganäs, Marion E. Meijer-van Gelder, Cees Cornelisse, Cassandra J. C. Claassen, Henk Portengen, Bert Bakker, Jan G. M. Klijn

Cancer Res (2000) 60 (8): 2155–2162.

Published: 01 April 2000

View articletitled, Complete Sequencing of TP53 Predicts Poor Response to Systemic Therapy of Advanced Breast Cancer

Journal Articles

The Urokinase System of Plasminogen Activation and Prognosis in 2780 Breast Cancer Patients

John A. Foekens, Harry A. Peters, Maxime P. Look, Henk Portengen, Manfred Schmitt, Michael D. Kramer, Nils Brünner, Fritz Jänicke, Marion E. Meijer-van Gelder, Sonja C. Henzen-Logmans, Wim L. J. van Putten, Jan G. M. Klijn

Cancer Res (2000) 60 (3): 636–643.

Published: 01 February 2000

View articletitled, The Urokinase System of Plasminogen Activation and Prognosis in 2780 Breast Cancer Patients

Journal Articles

Plasminogen Activator Inhibitor-2: Prognostic Relevance in 1012 Patients with Primary Breast Cancer

John A. Foekens, Frank Buessecker, Harry A. Peters, Ute Krainick, Wim L. J. van Putten, Maxime P. Look, Jan G.M. Klijn, Michael D. Kramer

Cancer Res (1995) 55 (7): 1423–1427.

Published: 01 April 1995

View articletitled, Plasminogen Activator Inhibitor-2: Prognostic Relevance in 1012 Patients with Primary Breast Cancer

Update search

NARROW

Format

Journal

Article Type

Issue Section

Date

Availability

Abstract 1611: 4-protein signature predicts outcome to tamoxifen treatment in estrogen receptor positive recurrent breast cancer

Abstract P4-09-03: Comparative proteomic analysis identifies a 15-protein signature related to clinical outcome of triple negative breast cancer

Abstract 3668: Relevance of BCAR4 in tamoxifen resistance and tumor aggressiveness of breast cancer

Abstract 1582: Identification of BCAR genes relevant for breast cancer progression and endocrine therapy resistance

PITX2B mRNA expression is associated with poor prognosis in lymph node-negative steroid hormone receptor-positive breast cancer

FGFR 4 predicts failure on tamoxifen therapy in women with recurrent breast cancer.

Association of DNA Methylation of Phosphoserine Aminotransferase with Response to Endocrine Therapy in Patients with Recurrent Breast Cancer

DNA-hypermethylation of PITX2 and risk of breast cancer recurrence in lymph node-negative hormone receptor-positive breast cancer patients

VAV3 and its binding proteins SIAH2 and EZH2 predict tamoxifen resistance in metastatic breast carcinomas

A functional Luteinizing Hormone Receptor variant predicts poor disease free survival of breast cancer patients.

Urokinase-Type Plasminogen Activator System in Breast Cancer: Association with Tamoxifen Therapy in Recurrent Disease

Stereo selective anti-tumor and anti-metastatic effects of the serine protease inhibitors: WX-UK1 and D-WX-UK1 administered to brown Norwegian rats bearing syngeneic BN-472 mammary tumor.

Quantitative BCAR1 protein levels in primary breast tumors are associated with early recurrence and failure of tamoxifen therapy

The Prognostic Value of Polymorphonuclear Leukocyte Elastase in Patients with Primary Breast Cancer

Enhanced Benefit from Adjuvant Chemotherapy in Breast Cancer Patients Classified High-Risk according to Urokinase-type Plasminogen Activator (uPA) and Plasminogen Activator Inhibitor Type 1 ( n = 3424)

High Tumor Levels of Vascular Endothelial Growth Factor Predict Poor Response to Systemic Therapy in Advanced Breast Cancer

Thymidine Kinase and Thymidylate Synthase in Advanced Breast Cancer: Response to Tamoxifen and Chemotherapy

Complete Sequencing of TP53 Predicts Poor Response to Systemic Therapy of Advanced Breast Cancer

The Urokinase System of Plasminogen Activation and Prognosis in 2780 Breast Cancer Patients

Plasminogen Activator Inhibitor-2: Prognostic Relevance in 1012 Patients with Primary Breast Cancer

Email alerts

AACR Journals

Update search

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only